Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
| ▸ | THRB | P10828 | 10/20 | 0.47 |
| ▸ | THRA | P10827 | 5/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10420836 | 0.93 | MEN1 (0.72) | MEN1NR1I2KMT2ATHRBTHRA | |
| Diclazuril SCHEMBL126138 | 0.91 | MEN1 (1.00) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL9823618 | 0.89 | MEN1 (0.83) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL10671723 | 0.88 | MEN1 (0.66) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL10421447 | 0.88 | MEN1 (0.65) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL10403617 | 0.86 | KMT2A (0.78) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL7919703 | 0.84 | MEN1 (0.86) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL10675273 | 0.84 | MEN1 (0.58) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL10420205 | 0.81 | MEN1 (0.82) | MEN1NR1I2KMT2ATHRBTHRA | |
| Letrazuril SCHEMBL7180358 | 0.81 | MEN1 (0.56) | MEN1NR1I2KMT2ATHRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 947 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014026707-A1 | ANTI-VAGINITIS COMPOSITIONS WITH IMPROVED RELEASE AND ADHERENCE | EDKO PAZARLAMA TANITIM TICARET LIMITED SIRKETI (TR) | 2014-02-20 | — | — | WO | claimed |
| WO-2014027006-A1 | BIOADHESIVE FORMULATIONS FOR USE IN DRUG DELIVERY | EDKO PAZARLAMA TANITIM TICARET LIMITED SIRKETI (TR) | 2014-02-20 | — | — | WO | claimed |
| WO-2013057208-A1 | COMPOSITIONS AND METHODS FOR REDUCING THE PROLIFERATION AND VIABILITY OF MICROBIAL AGENTS | TARGETED DELIVERY TECHNOLOGIES LIMITED (MT) | 2013-04-25 | — | — | WO | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1119255-A4 | NOVEL COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF PROTOZOAL DISEASE | NEW ACE RES COMPANY (US) | 2009-04-15 | — | — | EP | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| CN-1189175-C | Novel compsns. and methods for prevention and treatment of protozoal disease | NEW ACE RES CO (US) | 2005-02-16 | — | — | CN | claimed |
| US-20030096815-A1 | Novel compositions and methods for prevention and treatment of protozoal disease | NEW ACE RESEARCH COMPANY | 2003-05-22 | — | — | US | claimed |
| US-6465460-B1 | TRIAZINEDIONE OR TRIONE SUCH AS DICLAZURIL, TOLTRAZURIL OR SULFONOTOLTRAZURIL; SIDE EFFECT REDUCTION; ANTICOCCIDIAL AGENTS; EQUINE PROTOZOAL MYELOENCEPHALITIS, CRYPTOSPORIDIOSIS, BABESIOSIS | NEW ACE RESEARCH COMPANY | 2002-10-15 | — | — | US | claimed |
| CN-1331561-A | Novel compsns. and methods for prevention and treatment of protozoal disease | NEW ACE RES CO (US) | 2002-01-16 | — | — | CN | claimed |
| EP-1119255-A2 | NOVEL COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF PROTOZOAL DISEASE | New Ace Research Company (US) | 2001-08-01 | — | — | EP | claimed |
| WO-2001026660-A1 | NOVEL COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF PROTOZOAL DISEASE | NEW ACE RESEARCH COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| WO-2000019964-A2 | NOVEL COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF PROTOZOAL DISEASE | NEW ACE RESEARCH COMPANY (US) | 2000-04-13 | — | — | WO | claimed |
| US-5883095-A | TRIAZINE ANTICOCCIDAL USING CLAZURIL, DICLAZURIL, TOLTRAZURIL OR LETRAZURIL | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1999-03-16 | — | — | US | claimed |
| WO-1998043644-A1 | FORMULATIONS AND METHODS TO TREAT AND PREVENT EQUINE PROTOZOAL MYELOENCEPHALITIS | GRANSTROM DAVID (US) | 1998-10-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096815-A1 | Novel compositions and methods for prevention and treatment of protozoal disease | IL15, IL5, IL15RA | MEN1 2896/4885NR1I2 3228/4885KMT2A 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.